CRL icon

Charles River Laboratories

149.13 USD
-1.90
1.26%
Updated Jun 17, 10:03 AM EDT
1 day
-1.26%
5 days
-1.52%
1 month
5.48%
3 months
-14.79%
6 months
-21.23%
Year to date
-18.35%
1 year
-28.44%
5 years
-16.29%
10 years
107.10%
 

About: Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Employees: 20,100

0
Funds holding %
of 7,299 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0.03% less ownership

Funds ownership: 103.58% [Q4 2024] → 103.55% (-0.03%) [Q1 2025]

12% less funds holding

Funds holding: 628 [Q4 2024] → 552 (-76) [Q1 2025]

16% less call options, than puts

Call options by funds: $106M | Put options by funds: $125M

20% less capital invested

Capital invested by funds: $10B [Q4 2024] → $7.96B (-$2.04B) [Q1 2025]

22% less repeat investments, than reductions

Existing positions increased: 186 | Existing positions reduced: 237

47% less first-time investments, than exits

New positions opened: 70 | Existing positions closed: 133

50% less funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 2 (-2) [Q1 2025]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$140
6%
downside
Avg. target
$160
8%
upside
High target
$182
22%
upside

5 analyst ratings

positive
20%
neutral
80%
negative
0%
Redburn Atlantic
Jamie Clark
22%upside
$182
Buy
Upgraded
23 May 2025
Barclays
Luke Sergott
4%upside
$155
Equal-Weight
Maintained
8 May 2025
Baird
Eric Coldwell
6%downside
$140
Neutral
Maintained
8 May 2025
Mizuho
Ann Hynes
4%upside
$155
Neutral
Maintained
9 Apr 2025
Goldman Sachs
Matthew Sykes
14%upside
$170
Neutral
Downgraded
21 Mar 2025

Financial journalist opinion

Based on 6 articles about CRL published over the past 30 days

Neutral
Business Wire
1 day ago
Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River today announced a recycling program, developed in partnership with TerraCycle to give new life to single-use plastic cartridges.
Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment
Negative
Zacks Investment Research
1 week ago
Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?
Positive
Zacks Investment Research
2 weeks ago
Charles River Stock May Gain From Extended CHDI Research Deal on HD
CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.
Charles River Stock May Gain From Extended CHDI Research Deal on HD
Neutral
Business Wire
2 weeks ago
Charles River Laboratories to Present at William Blair and Jefferies Conferences
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at William Blair and Jefferies Conferences.
Charles River Laboratories to Present at William Blair and Jefferies Conferences
Neutral
Business Wire
2 weeks ago
Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington's Disease Research
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and CHDI announce an extension of their partnership, having worked together since 2005 to expedite therapies for Huntington's disease.
Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington's Disease Research
Positive
Zacks Investment Research
4 weeks ago
Should You Continue to Hold Charles River Stock in Your Portfolio?
CRL stays on investors' radars due to the strength of partnerships and segmental prospects.
Should You Continue to Hold Charles River Stock in Your Portfolio?
Neutral
Zacks Investment Research
1 month ago
Understanding Charles River (CRL) Reliance on International Revenue
Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Understanding Charles River (CRL) Reliance on International Revenue
Neutral
Business Wire
1 month ago
Charles River Laboratories to Present at Bank of America Health Care Conference
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Bank of America Health Care Conference.
Charles River Laboratories to Present at Bank of America Health Care Conference
Positive
CNBC
1 month ago
Activist Elliott reaches key agreement with Charles River. Here are three ways to create value
The firm has three possible paths toward value creation at the drug development company.
Activist Elliott reaches key agreement with Charles River. Here are three ways to create value
Neutral
Investopedia
1 month ago
S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments
The S&P 500 broke a two-session losing streak, rising Wednesday as stocks gained ground in volatile trading following the Federal Reserve's decision to keep interest rates unchanged.
S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments
Charts implemented using Lightweight Charts™